Roche releases genomic profiling kit for cancer research

By The Science Advisory Board staff writers

October 25, 2021 -- Roche has released a new genomic profiling kit for cancer research called the Avenio Tumor Tissue Comprehensive Genomic Profiling (CGP) kit.

Roche developed the Avenio kit in collaboration with its subsidiary, Foundation Medicine. The CGP kit offers information on genomic signatures like tumor mutational burden, microsatellite instability and loss of heterozygosity. The Avenio kit uses a gene panel based on the FoundationOne platform. It runs on Illumina's NextSeq 500/5500 RUO and NextSeq 550 Dx systems, Roche said. One kit can handle 24 samples and produces results in five days.

The Avenio Tumor Tissue CGP kit is a research-use-only next-generation sequencing test that provides an end-to-end workflow from DNA extraction and library preparation to the generation of variant results by the FoundationOne analysis platform via Avenio Connect. The kit uses a gene panel based on the FoundationOne platform that was designed to match the FoundationOne CDx panel content to analyze 324 cancer-related genes across four main classes of genomic alterations and genomic signatures known to cause and drive cancer. These genes provide valuable genomic insights and deepen the understanding of cancer biology.

The firm plans to launch Avenio in Asia, Europe, North America, and South America.

Shape Therapeutics, Roche to advance AAV-based RNA editing tech
Shape Therapeutics and Roche have inked a strategic collaboration and licensing agreement to develop gene therapies for Alzheimer's disease, Parkinson's...
Moderna to use Roche tests in COVID-19 vaccine trials
Moderna will use Roche's Elecsys anti-SARS-CoV-2 S antibody test in its messenger RNA (mRNA)-1273 vaccine research trials. The test can quantitatively...
EMA recommends approval of Roche's mAb breast cancer product
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use has recommended the approval of Roche's Phesgo, a fixed-dose combination...
Dyno Therapeutics licenses AAV platform to Roche
Dyno Therapeutics has licensed its CapsidMap platform for the development of next-generation adeno-associated virus (AAV) vectors for gene therapies for...
Regeneron, Roche increase supply of COVID-19 antibody cocktail
Regeneron Pharmaceuticals and Roche are joining forces to develop, manufacture, and distribute Regn-COV2, Regeneron's investigational antiviral antibody...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter